Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Current Predictors of Atrial Fibrillation Progression

https://doi.org/10.20996/1819-6446-2019-15-2-149-158

Full Text:

Abstract

Aim. To identify predictors of progression of atrial fibrillation (AF) in patients with hypertension (HT), coronary heart disease (CHD) and chronic heart failure (CHF) with recurrent AF.

Material and methods. The study included 31 2 patients with recurrent AF. The patients were divided into 3 groups according to a leading underlying condition: essential HT (n=1 36), CHD (n=11 2), and CHF with III-IV functional class by NYHA (n=64). The average follow-up duration was 60±3 months. Progression of AF was defined as development of long-standing persistent or permanent AF.

Results. All three groups of patients with recurrent AF revealed progression of the arrhythmia from paroxysmal or persistent to a sustained permanent form during the 5-year prospective follow-up. The rate of AF progression in the patients with CHF was significantly higher and accounted for 59% as compared to 46% in the patients with hypertension (p=0.002) and 51% in the patients with CHD (p=0.008). AF progression in patients with HT correlated significantly with left ventricular (LV) hypertrophy (odds ratio [OR] 1.25; 95% confidence interval [95%CI] 1.03-1.52) and increased arterial wall stiffness (OR 2.3; 95%CI 1.95-2.65). The independent predictors of arrhythmia progression in patients with CHD were a history of myocardial infarction (OR 1.23; 95%CI 0.9-1.5), irreversible LV wall motion abnormalities (OR 1.41; 95%CI 1.1-1.7), and increased plasma level of N-terminal pro-A-type natriuretic peptide (Nt-proANP; OR 1.16; 95%CI 0.8-1.4). Reduction in LV ejection fraction below 40% (OR 0.84; 95%CI 0.7-0.89) and increased plasma N-terminal pro-B-type natriuretic peptide (Nt-proBNP; OR 2.3; 95%CI 1.93-2.67) were independent predictors of AF progression from persistent to permanent form in the patients with systolic heart failure.

Conclusion. Progression of AF is related to the underlying cardiovascular disease. The early vascular aging syndrome and LV hypertrophy are the main factors of AF progression in patients with HT. Previous myocardial infarction with irreversible hypokinesia is associated with AF progression in patients with CHD. Reduced LV ejection fraction and increased plasma BNP predict AF progression in patients with CHF.

About the Authors

V. I. Podzolkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Valery I. Podzolkov - MD, PhD, Professor, Head of Chair of Faculty Therapy №2.

Trubetskaya ul. 8-2, Moscow, 119991


A. I. Tarzimanova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Aida I. Tarzimanova - MD, PhD, Professor, Chair of Faculty Therapy №2.

Trubetskaya ul. 8-2, Moscow, 119991



References

1. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;1 2(1 0):1360-420. doi:10.1093/europace/euq350.

2. Friberg L., Rosenqvist M., Lip G.Y Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients ith atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1 500-10. doi:10.1093/eurheartj/ehr488.

3. Hobbs FR., Taylor C.J., Jan Geersing G. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol. 2016;23:460-73. doi:10.1177/2047487315571890.

4. Holmqvist F, Kim S, Steinberg B.A. ORBIT-AF Investigators. Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart. 2015;101 (1 1 ):894-9. doi:10.1136/heartjnl-2014-307043.

5. Heijman J., Voigt N., Nattel S., Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circulation Research. 2014;1 1 4(9):1 483-99. doi:10.1161/CIRCRESAHA.114.302226.

6. Jahangir A. Progression of Paroxysmal to Persistent Atrial Fibrillation: Factors Promoting the HATCH Score. Journal of the American College of Cardiology, 2010;55(8):732-4. doi:10.1016/j.jacc.2009.12.010.

7. Manolis A.J., Rosei E.A., Coca A. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens. 2012;30(2):239-52. doi:10.1097/HJH.0b013e32834f03bf.

8. Gami A.S., Hodge D.O., Herges R.M. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation J Am Coll Cardiol. 2007;49(5):565-71. doi:10.1016/j.jacc.2006.08.060.

9. Schoonderwoerd B.A. Smit M.D., Pen L., Van Gelder I.C. New risk factors for atrial fibrillation: causes of "not-so-lone atrial fibrillation". Europace. 2008;1 0(1 ):668-73. doi:10.1093/europace/eun124.

10. Sciarretta S., Pontremoli R., Rosei E.A. Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens. 2009;27(2):410-7. doi:10.1097/HJH.0b013e32831bc764.

11. Mitchell G.F, Vasan R.S. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297(7):709-1 5. doi:10.1001/jama.297.7.709.

12. Tereshchenko S.N., Zhirov I.V, Romanova N.V. et al. The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. Rational Pharmacotherapy in Cardiology. 2015; 1 1 (6):577-81. (In Russ.) doi:10.20996/1819-6446-2015-11-6-577-581.

13. Mont L., Guasch E. Atrial fibrillation progression: How sick is the atrium? Heart Rhythm. 2017;17:1 547-71. doi:10.1016/j.hrthm.2017.02.027.

14. De Vos CB., Breishardt J., Camm A.J. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J. 2012;163:887-93. doi :10.1016/j.ahj.2012.02.015.

15. Weckbach L.T MicroRNAsas a diagnostic tool for heart failure and atrial fibrillation Curr Opin Pharmacol. 2016;27:24-30. doi:10.1016/j.coph.2016.01.001.

16. Nattel S. From guidelines to bench: implications of unresolved clinical issues for basic investigations of atrial fibrillation mechanisms. Can J Cardiol. 2011 ;27(1 ):1 9-26. doi:10.1016/j.cjca.2010.11.004.

17. Youn J.Y, Zhang J., Zhang Y et al. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol. 2013;62:72-9. doi:10.1016/j.yjmcc.2013.04.019.

18. Van Oosten E.M., Hamilton A., Petsikas D. et al. Effect of preoperative obstructive sleep apnea on the frequency of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2014;113:919-23. doi:10.1016/j.amjcard.2013.11.047.

19. Im S.I., Chun K.J., Park S.J. et al. Long-term Prognosis of Paroxysmal Atrial Fibrillation and Predictors for Progression to Persistnt or Chronic Atrial Fibrillation in the Korean Population. J Korean Med Sci. 201 5;30(7):895-902. doi:10.3346/jkms.2015.30.7.895.


For citation:


Podzolkov V.I., Tarzimanova A.I. Current Predictors of Atrial Fibrillation Progression. Rational Pharmacotherapy in Cardiology. 2019;15(2):149-158. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-2-149-158

Views: 180


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)